BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 03 mag, 2011
    Siena Biotech S.p.A. announces Start of Phase II Studies with SEN0014196 for Huntington’s Disease
    NicOx and Ferrer enter into option agreement for naproxcinod
    MolMed and Fondazione Telethon to collaborate on gene therapy for six rare diseases
    Bio3 Research S.r.l. appoints V.I.Pharma as exclusive distributor of the dietary supplement Biocysan in Greece
    Archimede R&D honoured by the 2011 Environment Enterprise Award
  • 15 mar, 2011
    Aptuit optimizes use of dried blood spot assays for customers
    ViroStatics Demonstrates Clinical Proof of Concept for Dual Antiviral Anti-Hyperactivation AV-HALT Drugs
    BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
  • 01 mar, 2011
    Toscana Life Sciences Foundation and Kedrion announce a collaboration agreement
    Siena Biotech and Pierrel Research together in Research & Development of new drugs “Made in Italy”
    Accelera announces the full accreditation by AAALAC International
    CHDI Foundation, Inc. and Siena Biotech S.p.A. enter collaboration to validate novel therapeutic targets for Huntington’s disease
    MolMed expands Phase III trial of NGR-hTNF for the treatment of mesothelioma in other European countries
    BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
  • 15 feb, 2011
    Biotechgate welcomes Assobiotec as co-partner for the Italian Biotech Database
    Orphan Drug Designation for Begedina 
    Abraxane available on the Italian market
    MolMed: Clinical Cancer Research publishes the results of a Phase I trial of NGR-hTNF in combination therapy with cisplatin
    FlyLife: genetic testing for health gain, now also in Europe
    BIO-Europe Spring 2011 returns to Milan, Italy
    BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
    Assobiotec visits Vienna and Innsbruck Life Science clusters
  • 01 feb, 2011
    Save the new date: BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
    MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States
    DIESSE Ricerche and Toscana Biomarkers announce a R&D collaboration agreement
    Newron Pharmaceuticals raises CHF3.5m in a private placement
    Genovax completes the recruitment of the patients for the Phase I/II clinical study for GX301
  • 03 dic, 2010
    NicOx: NCX 6560 phase 1b results presented at AHA
    Science and Technology Park of Sicily
    MolMed: first results of three clinical trials of NGR-hTNF presented at ECCO-ESMO 2010
    NicOx’s partner Bausch + Lomb initiates phase 2b study with glaucoma drug-candidate BOL-303259-X (NCX 116)
  • 05 nov, 2010
    BioInItaly Investment Forum and Intesa Sanpaolo Start-Up Initiative to be held in Milan from March 16 to March 17, 2011
    Eurand Presents Data on ZENPEP without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients with CF and Pancreatic Insufficiency
    PolyTherics moves lead candidate into development and manufacturing with DSM BioSolutions
    MolMed starts a randomised Phase II trial of NGR-hTNF in a new indication, soft tissue sarcomas
  • 20 ott, 2010
    MolMed: NGR-hTNF among the “Top 10 most interesting oncology projects to watch”
    NAICONS leads two projects awarded more than 3M€ for the development of two new promising antibiotics
    Aptuit and Siena Biotech Announce Strategic Relationship in Italy: new models of R&D help to advance compounds in key disease areas
  • 01 lug, 2010
    SOFIMAC PARTNERS launches the fund Technology and Health 1 with first Italian investment
    Axxam and partners awarded EUR 1.5 million by the Regione Lombardia (Metadistretti) to support a drug discovery project on a new key metabolic enzyme
    MolMed leads a project awarded a € 1.4 million grant by Regione Lombardia for optimisation of TK therapy manufacturing process
    Bio3 Research exercised an option for exclusive license from Protelica, Hayward, California, for mimic-antibody antagonists to HMGB1
    MolMed Share Capital Increase via Pre-emptive Rights Offering
    Axxam and Lonza Announce the Signing of a License Agreement for the Use of Axxam’s Photoproteins in Lonza’s Calcium Biosensors
    Presentation of preclinical data for NicOx’s ophthalmology candidate NCX 434
  • 26 mag, 2010
    Alessandro Sidoli appointed President of Assobiotec for the 3-years period 2010-2012
    Bio3 Research Patent Granting in Mexico
    MAVI Sud attends Skin Nutrition, Cosmetic & Personal Care Industry Forum 2010
  • 05 mag, 2010
    Presented in Milan the Report “Biotechnology in Italy 2010”. The Italian biotech is young but rapidly growing
    Italy at Bio 2010
    NiKem Research Receives Authorization for Rodent Toxicology Studies
    bioPmed/Bioindustry Park Silvano Fumero signed a partnership agreement with Lyonbiopole
    Pooled phase 3 blood pressure results for NicOx’s naproxcinod presented at the American Society of Hypertension
  • 15 apr, 2010
    Siena Biotech’s news
    Polyphor Ltd and Axxam S.p.A. Announce Ion Channel Collaboration
    Adienne Pharma & Biotech: exclusive European marketing authorization throughout for the orphan medicinal product for human use Tepadina
    MolMed starts Phase III trial of NGR-hTNF in mesothelioma
    NiKem Research Receives Qualification for Bioanalysis of Clinical Samples